Key result
JNK1 inhibition selectively suppresses LPS-induced CD14/SR-AI expression and macrophage foam cell formation.
Answers are grounded in this paper and cite their sources.
Foam cell formation is the key process in the development of atherosclerosis. The uptake of oxidized low-density lipoprotein (oxLDL) converts macrophages into foam cells. We recently reported that lipopolysaccharide (LPS)-induced foam cell formation is regulated by CD14 and scavenger receptor AI (SR-AI). In this study, we employed pharmaceutical and gene knockdown approaches to determine the upstream molecular mediators, which control LPS-induced foam cell formation. Our results demonstrated that the specific c-Jun N-terminal kinase (JNK) pathway inhibitor, SP600125, but neither the specific inhibitor of extracellular signaling-regulated kinase (ERK) kinase MEK1/2, U0126, nor the specific inhibitor of p38 MAPK, SB203580, significantly blocks LPS-induced oxLDL uptake, suggesting that the JNK pathway is the upstream mediator of LPS-induced oxLDL uptake/foam cell formation. To address whether JNK pathway mediates LPS-induced oxLDL uptake is due to JNK pathway-regulated CD14 and SR-AI expression, we assessed whether the pharmaceutical inhibitor of JNK influences LPS-induced expression of CD14 and SR-AI. Our results indicate that JNK pathway mediates LPS-induced CD14 and SR-AI expression. To conclusively address the isoform role of JNK family, we depleted JNK isoforms using the JNK isoform-specific siRNA. Our data showed that the depletion of JNK1, but not JNK2 blocked LPS-induced CD14/SR-AI expression and foam cell formation. Taken together, our results reveal for the first time that JNK1 is the key mediator of LPS-induced CD14 and SR-AI expression in macrophages, leading to LPS-induced oxLDL uptake/foam cell formation. We conclude that the novel JNK1/CD14/SR-AI pathway controls macrophage oxLDL uptake/foam cell formation.
No takes yet. Share an insight, caveat, or question.
An et al. (2018) studied Atherosclerosis / macrophage foam cell formation. JNK pathway inhibition (SP600125) and JNK1 siRNA knockdown vs. MEK1/2 inhibition (U0126), p38 MAPK inhibition (SB203580), and JNK2 siRNA knockdown was evaluated on LPS-induced CD14/SR-AI expression, oxLDL uptake, and macrophage foam cell formation. JNK pathway inhibition (SP600125) and JNK1 siRNA depletion, unlike ERK, p38, or JNK2 blockade, significantly blocked LPS-induced CD14/SR-AI expression and macrophage foam cell formation.
Synapse has enriched 10 related papers. Consider them for comparative context: